Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 NSCLC 3 Adenocarcinoma of Lung 2 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 Meningeal Carcinomatosis 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Adenocarcinoma 1

Interventions

pembrolizumab 4 anlotinib 4 sintilimab 3 Paclitaxel 3 Leucovorin 3 Cetuximab 3 niraparib 2 Sorafenib 2 Radiotherapy 2 Nivolumab 2 Hyperthermic Intraperitoneal Chemotherapy 2 Gemcitabine 2 Fluorouracil 2 Drug Therapy 2 Docetaxel 2 Cisplatin 2 vistusertib 1 titanium silicide 1 tislelizumab 1 tirbanibulin 1 surufatinib 1 regorafenib 1 pemigatinib 1 olaparib 1 elemene 1 durvalumab 1 donafenib 1 daromun 1 avelumab 1 aumolertinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinoma × aflutinib × Clear all

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡